A drug for an aggressive form of eye cancer is being fast-tracked to patients by the NHS across England. One patient receiving the treatment described the rollout as “the best early Christmas present ...
Outlook said it remains confident that ONS-5010, marketed as Lytenava in the EU, is an important therapy for the treatment of wet age-related macular degeneration in place of off-label repackaged ...